Related Experiment Video
Updated: Jan 9, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.0K
Yttrium-90 Radioembolization for Androgen-Independent Prostate Cancer Metastasis to the Liver
Mohamad M Alzein1, Andrew C Gordon1, Maha H Hussain2
1Northwestern University, Department of Radiology, Section of Interventional Radiology, Chicago, Illinois (M.M.A., A.C.G., R.S., R.J.L.).
Academic Radiology
|November 30, 2025
Summary
Transarterial radioembolization (TARE) shows antitumor effects and manageable toxicity for prostate cancer liver metastases. Further research is needed to determine optimal treatment timing for this therapy.
Area of Science:
- Interventional Radiology
- Oncology
- Nuclear Medicine
Background:
- Androgen-independent prostate cancer (AIPC) with liver metastasis presents a significant treatment challenge.
- Transarterial radioembolization (TARE) is an emerging therapeutic option for liver-dominant malignancies.
Purpose of the Study:
- To report the outcomes of patients with AIPC liver metastases treated with TARE using yttrium-90 (Y90).
- To evaluate the efficacy and safety of TARE in this patient population.
Main Methods:
- A retrospective review of seven patients treated with Y90 TARE between 2007 and January 2024.
- Tumor response assessed using RECIST v1.1 criteria.
- Survival and adverse events analyzed using Kaplan-Meier and CTCAE v5, respectively.
Main Results:
- 50% of patients achieved partial response and 50% had stable disease; no index tumor progression observed by RECIST.
- Median time-to-progression was 2.3 months, hepatic progression 2.8 months, and extrahepatic progression 7.0 months.
- Median overall survival was 16.2 months with manageable toxicity, including one CTCAE grade 3 fatigue event.
Conclusions:
- TARE demonstrates significant antitumor activity in patients with AIPC liver metastases.
- The toxicity profile of TARE appears manageable in this cohort.
- Optimal timing for TARE in AIPC liver metastasis requires further investigation.
